Atlas Trials

Bioverativ, a Sanofi company

16 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Bioverativ, a Sanofi company

RecordFirmDate
To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD) (NCT04770935)Bioverativ, a Sanofi company2021-05-03
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (NCT04658472)Bioverativ, a Sanofi company2021-04-28
Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088 (NCT04802057)Bioverativ, a Sanofi company2021-03-22
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A (NCT04644575)Bioverativ, a Sanofi company2021-02-23
Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A (NCT04759131)Bioverativ, a Sanofi company2021-02-19
A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP) (NCT04669600)Bioverativ, a Sanofi company2021-02-04
A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease (NCT04269551)Bioverativ, a Sanofi company2020-06-15
A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A (NCT04161495)Bioverativ, a Sanofi company2019-11-19
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion (NCT03347422)Bioverativ, a Sanofi company2018-03-17
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study) (NCT03347396)Bioverativ, a Sanofi company2018-03-05
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study) (NCT03093480)Bioverativ, a Sanofi company2017-12-08

Track Bioverativ, a Sanofi company automatically

Every clearance here is in the API, with alerts when new ones post.